ArticleOncoTargets and therapy2018
MicroRNA-300 suppresses metastasis of oral squamous cell carcinoma by inhibiting epithelial-to-mesenchymal transition.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR-300/RGMB axis.International journal of clinical oncology · 2023Article
- Role of miR-300-3p in Leydig cell function and differentiation: A therapeutic target for obesity-related testosterone deficiency.Molecular therapy. Nucleic acids · 2023Article
- Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.Bioengineered · 2022Article
- MiR-300 Alleviates Cell Proliferation and Migration and Facilitates Cell Apoptosis by Targeting c-Met in Gastric Cancer.Journal of oncology · 2022Article
- Cascades between miRNAs, lncRNAs and the NF-κB signaling pathway in gastric cancer (Review).Experimental and therapeutic medicine · 2021Review
- ET-1 Promotes Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells via the microRNA-489-3p /TWIST Axis.OncoTargets and therapy · 2021Article
- MicroRNA-300 Inhibits the Proliferation and Metastasis of Cervical Cancer Cells via Posttranscriptional Suppression of G Protein-Coupled Receptor 34 (GPR34).Journal of oncology · 2021Article
- Review
- WISP-1 Promotes Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells Via the miR-153-3p/Snail Axis.Cancers · 2019Article
- The Role of MicroRNAs in Recurrence and Metastasis of Head and Neck Squamous Cell Carcinoma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOral cancer is the sixth most prevalent form of cancer, with oral squamous cell carcinomas (OSCCs) exhibiting the highest morbidity of all head and neck cancers. However, the specific metastatic mechanism is not yet clear. MicroR-300 (miR-300) has been identified as a critical regulator in tumor development. In this study, we focused on the roles of miR-300 in regulating epithelial-mesenchymal transition (EMT) in OSCC.
methodsThe surgical specimens from cases of OSCC (N=120) were collected, and the miR-300 expression was tested and the results were analyzed for possible correlations with clinical characteristics, and the prognostic significance was assessed by Kaplan-Meier analysis and Cox proportional hazards regression in OSCC patients. In addition, the proliferation and invasion of OSCC cells were evaluated after transfection of miR-300 mimics or inhibitor. At last, the role of miR-300 in EMT was investigated.
resultsThe results showed that miR-300 levels were significantly lower in patients with OSCC than in controls and miR-300 levels in patients with OSCC were significantly associated with TNM classification. Kaplan-Meier analysis indicated that miR-300 with lower level had significantly decreased overall survival and disease-free survival of OSCC patients. In multivariate analysis, TNM stage, miR-300 expression and tobacco usage were the independent prognostic factors for overall survival and disease-free survival in OSCC. Moreover, in vitro experiments showed that miR-300 could inhibit the proliferation and invasion of OSCC cells. More importantly, miR-300 could inhibit the EMT process. In addition, we found that ET-1 could inhibit the expression of miR-300.
conclusionOur findings indicated that miR-300 could suppress metastasis of OSCC by inhibiting EMT. The present study indicates that miR-300 is a potential therapeutic agent for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.